AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response
AC Immune reported positive safety and immunogenicity results from Part 1 of its Phase 2 Parkinson's disease trial for ACI-7104.
Share
Why It Matters
AC Immune tested a new Parkinson's medicine on people. Everyone's body made the antibodies the medicine was supposed to create.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.